申请人:Vernalis (R&D) Ltd.
公开号:US11234987B2
公开(公告)日:2022-02-01
Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers:
wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —(C═S)—, —SO.sub.2-, —C(═O)O—, —C(═O)NRA—, —C(═S) NRA—, —SO2NRA—, —NRAC(═O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.
式(A)或(B)的异噁唑是 HSP90 活性的抑制剂,可用于治疗癌症等:
-C(═O)O-、-C(═O)NRA-、-C(═S) NRA-、-SO2NRA-、-NRAC(═O)-、-NRASO2- 或 -NRA-,其中 RA 是氢或 C1-C6 烷基,Q 是氢或任选取代的碳环或杂环基;R2 是 (i) 上式 (IA) 的基团或 (ii) 羧酰胺基;或 (iii) 非芳香碳环或杂环,其中环碳任选被式-(Alk1)p-(Z)r-(Alk2)s-Q 的基团取代,和/或环氮任选被式-(Alk1)p-(Z)r-(Alk2)s-Q 的基团取代,其中 Q、Alk1、Alk2、Z、p、r 和 s 如上文有关基团 (IA) 的定义;和 R3 是氢、任选取代的环烷基、环烯基、C1-C6 烷基、C1-C6 烯基或 C1-C6 烷炔基;或羧基、羧酰胺或羧基酯基团。